Ketamine Administration during the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice

Cerebral Cortex

Volumn 26, Issue 3, 2016, Pages 1117-1129

  Jeevakumar, Vivek ^a   Kroener, Sven ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cortical disinhibition; developmental NMDAR antagonism; glutamate; parvalbumin; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PARVALBUMIN; AMPA RECEPTOR; NR2A NMDA RECEPTOR; NR2B NMDA RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EVOKED RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC SYSTEM; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PATCH CLAMP TECHNIQUE; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SPIKE; ACTION POTENTIAL; ANIMAL; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; INHIBITORY POSTSYNAPTIC POTENTIAL; METABOLISM; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SYNAPSE; TRANSGENIC MOUSE;

ACTION POTENTIALS; ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; GAMMA-AMINOBUTYRIC ACID; IMMUNOHISTOCHEMISTRY; INHIBITORY POSTSYNAPTIC POTENTIALS; KETAMINE; MALE; MICE, TRANSGENIC; PARVALBUMINS; PATCH-CLAMP TECHNIQUES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPSES;

EID: 84961262971     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhu293     Document Type: Article

References (83)

1. AbekawaT, Ito K, Nakagawa S, Koyama T. 2007. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine. Psychopharmacology (Berl). 192:303-316.
2. Akbarian S, Huang H-S. 2006. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 52:293-304.
3. Bayer SA, Altman J, Russo RJ, Zhang X. 1993. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology. 14:83-144.
4. Beasley CL, Reynolds GP. 1997. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res. 24:349-355.
5. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, Dugan LL. 2007. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 318:1645-1647.
6. Beierlein M, ConnorsBW. 2002. Short-term dynamics of thalamocortical and intracortical synapses onto layer 6 neurons in neocortex. J Neurophysiol. 88:1924-1932.
7. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K. 2010. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 13:76-83.
8. Benes FM, Berretta S. 2001. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 25:1-27.
9. Bitanihirwe BKY, Lim MP, Kelley JF, Kaneko T, Woo TUW. 2009. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry. 9:71.
10. Bonci A, Malenka RC. 1999. Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci. 19:3723-3730.
11. Braun I, Genius J, Grunze H, Bender A, Möller H-J, Rujescu D. 2007. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res. 97:254-263.
12. Brown AS, Derkits EJ. 2010. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 167:261-280.
13. Chatterjee M, Verma R, Ganguly S, Palit G. 2012. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 63:1161-1171.
14. Chattopadhyaya B, Di Cristo G, Higashiyama H, Knott GW, Kuhlman SJ, Welker E, Huang ZJ. 2004. Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci. 24:9598-9611.
15. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. 2003. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology. 28:265-275.
16. Coleman MJ, Cestnick L, Krastoshevsky O, Krause V, Huang Z, Mendell NR, Levy DL. 2009. Schizophrenia patients show deficits in shifts of attention to different levels of global-local stimuli: evidence for magnocellular dysfunction. Schizophr Bull. 35:1108-1116.
17. Dantzker JL, Callaway EM. 2000. Laminar sources of synaptic input to cortical inhibitory interneurons and pyramidal neurons. Nat Neurosci. 3:701-707.
18. EylesDW, McGrath JJ, Reynolds GP. 2002. Neuronal calcium-binding proteins and schizophrenia. Schizophr Res. 57:27-34.
19. Gabbott PL, Dickie BG, Vaid RR, Headlam AJ, Bacon SJ. 1997. Localcircuit neurones in the medial prefrontal cortex (areas 25, 32 and 24b) in the rat: morphology and quantitative distribution. J Comp Neurol. 377:465-499.
20. Galarreta M, Hestrin S. 2001. Spike transmission and synchrony detection in networks of GABAergic interneurons. Science. 292:2295-2299.
21. GalarretaM,Hestrin S. 2002. Electrical and chemical synapses among parvalbumin fast-spiking GABAergic interneurons in adult mouse neocortex. Proc Natl Acad Sci USA. 99:12438-12443.
22. Gonzalez-Burgos G, Kroener S, Seamans JK, Lewis DA, Barrionuevo G. 2005. Dopaminergic modulation of shortterm synaptic plasticity in fast-spiking interneurons of primate dorsolateral prefrontal cortex. J Neurophysiol. 94:4168-4177.
23. Gonzalez-Burgos G, Lewis DA. 2012. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull. 38:950-957.
24. Halasy K, Buhl EH, Lörinczi Z, Tamás G, Somogyi P. 1996. Synaptic target selectivity and input of GABAergic basket and bistratified interneurons in the CA1 area of the rat hippocampus. Hippocampus. 6:306-329.
25. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA. 2003. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 23:6315-6326.
26. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andradé M, Tankou S, et al. 2007. Dominantnegative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA. 104:14501-14506.
27. Homayoun H, MoghaddamB. 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 27:11496-11500.
28. Ikonomidou C, Mosinger JL, Salles KS, Labruyere J, Olney JW. 1989. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci. 9:2809-2818.
29. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1301-1308.
30. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:201-225.
31. Kaalund SS, Riise J, Broberg BV, Fabricius K, Karlsen AS, Secher T, Plath N, Pakkenberg B. 2013. Differential expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. J Neurochem. 124:548-557.
32. Kawaguchi Y, Kondo S. 2002. Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. J Neurocytol. 31:277-287.
33. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. 2006. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci. 26:1604-1615.
34. Kjaerby C, Broberg BV, Kristiansen U, Dalby NO. 2014. Impaired GABAergic Inhibition in the Prefrontal Cortex of Early Postnatal Phencyclidine (PCP)-Treated Rats. Cereb Cortex. 24:2522-2532.
35. Krystal JH, Anand A, Moghaddam B. 2002. Effects ofNMDAReceptor Antagonists: Implications for the Pathophysiology of Schizophrenia. Arch Gen Psychiatry. 59:663-664.
36. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:199-214.
37. Lahti AC, Koffel B, LaPorte D, Tamminga CA. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:9-19.
38. Lewis DA, Curley AA, Glausier JR, Volk DW. 2012. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 35:57-67.
39. Lewis DA, Hashimoto T, Volk DW. 2005. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 6:312-324.
40. Lewis DA, Lieberman JA. 2000. Catching up on schizophrenia: natural history and neurobiology. Neuron. 28:325-334.
41. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. 2008. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31:234-242.
42. Liu F, Patterson TA, Sadovova N, Zhang X, Liu S, Zou X, Hanig JP, Paule MG, Slikker W Jr, Wang C. 2013. Ketamine-induced neuronal damage and altered N-methyl-D-aspartate receptor function in rat primary forebrain culture. Toxicol Sci. 131:548-557.
43. Liu F, Paule MG, Ali S,Wang C. 2011. Ketamine-induced neurotoxicity and changes in gene expression in the developing rat brain. Curr Neuropharmacol. 9:256-261.
44. Liu X-B, Murray KD, Jones EG. 2004. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci. 24:8885-8895.
45. Lodge DJ, Behrens MM, Grace AA. 2009. A loss of parvalbumincontaining interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 29:2344-2354.
46. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:141-150.
47. Martina M, Schultz JH, Ehmke H, Monyer H, Jonas P. 1998. Functional and molecular differences between voltage-gated K+ channels of fast-spiking interneurons and pyramidal neurons of rat hippocampus. J Neurosci. 18:8111-8125.
48. Matta JA, Ashby MC, Sanz-Clemente A, RocheKW, Isaac JTR. 2011. mGluR5 and NMDA receptors drive the experience-and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron. 70:339-351.
49. Minzenberg MJ, Firl AJ, Yoon JH, Gomes GC, Reinking C, Carter CS. 2010. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. Neuropsychopharmacology. 35:2590-2599.
50. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:529-540.
51. Mouri A, Noda Y, Enomoto T, Nabeshima T. 2007. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 51:173-184.
52. Nakatani-Pawlak A, Yamaguchi K, Tatsumi Y, Mizoguchi H, Yoneda Y. 2009. Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull. 32:1576-1583.
53. Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE. 2012. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology. 62:1574-1583.
54. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 20:106-118.
55. Olney JW, Farber NB. 1995. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 13:335-345.
56. Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 33:523-533.
57. Owczarek S, Hou J, Secher T, Kristiansen LV. 2011. Phencyclidine treatment increases NR2A and NR2B N-methyl-D-aspartate receptor subunit expression in rats. Neuroreport. 22:935-938.
58. Paoletti P, Bellone C, Zhou Q. 2013. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 14:383-400.
59. Paxinos G, Franklin KBJ. 2008. The mouse brain in stereotaxic coordinates. 3rd ed. San Diego (CA): Academic Press.
60. Povysheva NV, Zaitsev AV, Rotaru DC, Gonzalez-Burgos G, Lewis DA, Krimer LS. 2008. Parvalbumin-positive basket interneurons in monkey and rat prefrontal cortex. J Neurophysiol. 100:2348-2360.
61. Powell SB, Sejnowski TJ, Behrens MM. 2012. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology. 62:1322-1331.
62. Rotaru DC, Lewis DA, Gonzalez-Burgos G. 2013. The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia. Rev Neurosci. 23:97-109.
63. Rotaru DC, Yoshino H, Lewis DA, Ermentrout GB, Gonzalez-Burgos G. 2011. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J Neurosci. 31:142-156.
64. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Möller H-J, et al. 2006. A pharmacological model for psychosis based on N-methyl-Daspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry. 59:721-729.
65. Sanchez-Vives MV, McCormick DA. 2000. Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci. 3:1027-1034.
66. Sohal VS, Zhang F, Yizhar O, Deisseroth K. 2009. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 459:698-702.
67. Somogyi P. 1977.Aspecific "axo-axonal" interneuron in the visual cortex of the rat. Brain Res. 136:345-350.
68. Somogyi P, Klausberger T. 2005. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol. 562:9-26.
69. Szabadics J, Varga C, Molnár G, Oláh S, Barzó P, Tamás G. 2006. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science. 311:233-235.
70. Taylor CW, Tovey SC. 2010. IP(3) receptors: toward understanding their activation. Cold Spring Harb Perspect Biol. 2:a004010.
71. Thomson AM, Bannister AP. 2003. Interlaminar connections in the neocortex. Cereb Cortex. 13:5-14.
72. Van De Werd HJJM, Rajkowska G, Evers P, Uylings HBM. 2010. Cytoarchitectonic and chemoarchitectonic characterization of the prefrontal cortical areas in the mouse. Brain Struct Funct. 214:339-353.
73. Waites CL, Craig AM, Garner CC. 2005. Mechanisms of vertebrate synaptogenesis. Annu Rev Neurosci. 28:251-274.
74. Wang H, Stradtman GG, Wang X-J, Gao W-J. 2008. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci USA. 105:16791-16796.
75. Wang H-X, Gao W-J. 2009. Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology. 34:2028-2040.
76. Wang H-X, GaoW-J. 2012. Prolonged exposure to NMDAR antagonist induces cell-type specific changes of glutamatergic receptors in rat prefrontal cortex. Neuropharmacology. 62:1808-1822.
77. Winterer G, Weinberger DR. 2004. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 27:683-690.
78. Woo T-UW,Walsh JP, Benes FM. 2004. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 61:649-657.
79. Woodruff A, Xu Q, Anderson SA, Yuste R. 2009. Depolarizing effect of neocortical chandelier neurons. Front Neural Circuits. 3:15.
80. Xi D, Keeler B, ZhangW, Houle JD, Gao W-J. 2009. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique. J Neurosci Methods. 176:172-181.
81. Yuan K, Fink KL, Winer JA, Schreiner CE. 2011. Local connection patterns of parvalbumin-positive inhibitory interneurons in rat primary auditory cortex. Hear Res. 274:121-128.
82. Zhang Y, Behrens MM, Lisman JE. 2008. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol. 100:959-965.
83. Zhang Z, Sun Q-Q. 2011. Development ofNMDANR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Dev Neurobiol. 71:221-245.